Help yourself to our online catalogue of useful information, including annual reports, scientific and clinical trial publications, infographics and more.
Our 2021 Annual Report documents our medicine development progress, highlights our achievements over the year, and presents our approach to looking forward and continuing our global presence.
Moxidectin for Onchocerciasis - Current Status and Next Steps Towards Implementation
October 2022
Learn about our latest Annual Report, attendance at ASTMH annual meeting, signing of the Kigali Declaration, job opportunities and more.
March 2022
Learn about progress in clinical development, team expansion, awards and more.
Our 2021 Annual Report documents our medicine development progress, highlights our achievements over the year, and presents our approach to looking forward and continuing our global presence.
December 2021
Learn about new lymphatic filariasis data for moxidectin, progress in clinical development, team expansion, awards and more.
September 2021
Learn about MDGH's expanded footprint, its progress in clinical development, a social impact investment opportunity, and the nominations for the Prix Galien Award for 2021
Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols: MDGH-MOX-3001: Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis (Target: approx. 1,000 participants).
Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols: MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas (Target: approx. 12,500 participants).
June 2021
A look at the 2020 MDGH Annual Report, clinical development updates, and the development of a new formulation of moxidectin for children.
March 2021
Learn more about MDGH's plans for its new investigational treatment for tuberculosis and leprosy types 2 reactions.
MDGH celebrated its 15th anniversary in 2020. Our 2020 Annual Report documents our progress as well as our current thinking on our contribution to neglected disease R&D and access to medicines.
Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216
Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother.2011;55(11):5200-5204.
Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582-589.
Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32-37.
Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.
Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.
Milton P, Hamley JID, Walker M, Basanez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Ther. 2020:1-15. 10.1080/14787210.2020.1792772
Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40-i48.
Please try again.
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523